Clinical Trials

Modified Chemotherapy Regimen Reduces Long-Term Side Effects in Hodgkin Lymphoma
Research & Development Modified Chemotherapy Regimen Reduces Long-Term Side Effects in Hodgkin Lymphoma

Hodgkin lymphoma, a rare but treatable blood cancer, primarily impacts younger individuals aged 20-40. Effective treatment is crucial, but so is the consideration of long-term health and quality of life for patients. Recent advancements in chemotherapy regimens have shown promise in reducing

Can Immunotherapy Before and After Surgery Improve NSCLC Outcomes?
Research & Development Can Immunotherapy Before and After Surgery Improve NSCLC Outcomes?

The PROSPECT-Lung trial has officially commenced, heralding a significant advance in the quest to enhance treatment strategies for patients with resectable non-small cell lung cancer (NSCLC). This trial marks the inaugural endeavor of the newly established National Cancer Institute (NCI) Clinical

High-Dose Chemotherapy and ASCT No Extra Benefit in MCL Remission
Research & Development High-Dose Chemotherapy and ASCT No Extra Benefit in MCL Remission

The findings from the late-breaking research presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition have brought new insights into the treatment of mantle cell lymphoma (MCL). The phase 3 study EA4151, conducted by the ECOG-ACRIN Cancer Research Group, investigated

Can High-Fructose Corn Syrup Fuel Cancer Growth and Spread?
Research & Development Can High-Fructose Corn Syrup Fuel Cancer Growth and Spread?

The relationship between dietary fructose, particularly from high-fructose corn syrup, and cancer growth is a topic of growing concern. Over the past few decades, the consumption of high-fructose corn syrup has skyrocketed. While naturally occurring fructose in fruits, vegetables, and honey is

Can Gene Therapy Offer a Breakthrough for Alzheimer’s Treatment?
Research & Development Can Gene Therapy Offer a Breakthrough for Alzheimer’s Treatment?

Alzheimer’s disease, a debilitating condition marked by progressive memory loss and cognitive decline, has long proven resistant to effective treatment, leaving millions of patients and their families searching for hope. Despite significant research efforts, traditional therapies targeting the

Patient-Derived Glioblastoma Organoids Advance Personalized CAR-T Therapy
Tech & Innovation Patient-Derived Glioblastoma Organoids Advance Personalized CAR-T Therapy

Researchers at the Perelman School of Medicine at the University of Pennsylvania have made a significant breakthrough in personalized medicine and cancer treatment. By using patient-derived glioblastoma (GBM) organoids, they have developed a method to model patient responses to CAR-T cell therapy

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later